SPECT/CT量化99m-TCPYP摄取量以评估ATTR心脏淀粉样变性的塔法米迪治疗反应

IF 3 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Nuclear Cardiology Pub Date : 2024-10-09 DOI:10.1016/j.nuclcard.2024.102056
Carlos Godoy-Rivas, Mohammed Elsadany, Abhishek Jaiswal, Adaya Weissler-Snir, Sabeena Arora, W Lane Duvall
{"title":"SPECT/CT量化99m-TCPYP摄取量以评估ATTR心脏淀粉样变性的塔法米迪治疗反应","authors":"Carlos Godoy-Rivas, Mohammed Elsadany, Abhishek Jaiswal, Adaya Weissler-Snir, Sabeena Arora, W Lane Duvall","doi":"10.1016/j.nuclcard.2024.102056","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiac imaging with bone-avid tracers for the diagnosis of transthyretin amyloid (ATTR) cardiac amyloidosis uses only limited quantification, but single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition can provide volumetric assessment with quantification of tracer uptake. Tafamidis is routinely used in the treatment of cardiac amyloidosis, but there are scant data on changes in imaging results during therapy. The purpose of this study was to perform a longitudinal assessment of Tc-99m-pyrophosphate (PYP) imaging to determine if tafamidis therapy results in any change in quantitative measures of tracer uptake.</p><p><strong>Methods: </strong>The study incorporated a prospective, single-center study of ATTR patients being treated with tafamidis using Tc-99m-PYP SPECT/CT to quantify cardiac tracer uptake in the whole heart and left ventricle. Standardized uptake values (SUVs) were adjusted for blood pool activity. Comparison of baseline activity was made to values obtained approximately every 6 months during treatment.</p><p><strong>Results: </strong>Twenty-two patients (77.0±7.5 years old, 86.4% male) were on tafamidis for 15.3±4.0 months, with an average time between baseline and final follow-up study of 16.8±4.7 months. Thirteen patients (59.1%) had multiple follow-up amyloid studies. Statistically significant reductions in total SUVs, SUV volume, and percentage of injected dose were seen. Adjusted for the maximal aortic SUV, the total SUV in the left ventricle decreased by 36.9%, the SUV volume by 38.7%, and the percentage of injected dose decreased by 34.9% (all P values≤0.0001). Over the study duration, there was a decrease of 7.7%/month in the measured metrics.</p><p><strong>Conclusion: </strong>The quantitative SUV measurements from Tc-99m-PYP SPECT/CT revealed an overall decrease in scintographic amyloid burden during the course of tafamidis therapy, but additional work is needed to determine the optimal metrics and improve the reproducibility of the quantification.</p>","PeriodicalId":16476,"journal":{"name":"Journal of Nuclear Cardiology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis.\",\"authors\":\"Carlos Godoy-Rivas, Mohammed Elsadany, Abhishek Jaiswal, Adaya Weissler-Snir, Sabeena Arora, W Lane Duvall\",\"doi\":\"10.1016/j.nuclcard.2024.102056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cardiac imaging with bone-avid tracers for the diagnosis of transthyretin amyloid (ATTR) cardiac amyloidosis uses only limited quantification, but single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition can provide volumetric assessment with quantification of tracer uptake. Tafamidis is routinely used in the treatment of cardiac amyloidosis, but there are scant data on changes in imaging results during therapy. The purpose of this study was to perform a longitudinal assessment of Tc-99m-pyrophosphate (PYP) imaging to determine if tafamidis therapy results in any change in quantitative measures of tracer uptake.</p><p><strong>Methods: </strong>The study incorporated a prospective, single-center study of ATTR patients being treated with tafamidis using Tc-99m-PYP SPECT/CT to quantify cardiac tracer uptake in the whole heart and left ventricle. Standardized uptake values (SUVs) were adjusted for blood pool activity. Comparison of baseline activity was made to values obtained approximately every 6 months during treatment.</p><p><strong>Results: </strong>Twenty-two patients (77.0±7.5 years old, 86.4% male) were on tafamidis for 15.3±4.0 months, with an average time between baseline and final follow-up study of 16.8±4.7 months. Thirteen patients (59.1%) had multiple follow-up amyloid studies. Statistically significant reductions in total SUVs, SUV volume, and percentage of injected dose were seen. Adjusted for the maximal aortic SUV, the total SUV in the left ventricle decreased by 36.9%, the SUV volume by 38.7%, and the percentage of injected dose decreased by 34.9% (all P values≤0.0001). Over the study duration, there was a decrease of 7.7%/month in the measured metrics.</p><p><strong>Conclusion: </strong>The quantitative SUV measurements from Tc-99m-PYP SPECT/CT revealed an overall decrease in scintographic amyloid burden during the course of tafamidis therapy, but additional work is needed to determine the optimal metrics and improve the reproducibility of the quantification.</p>\",\"PeriodicalId\":16476,\"journal\":{\"name\":\"Journal of Nuclear Cardiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nuclear Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.nuclcard.2024.102056\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nuclear Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.nuclcard.2024.102056","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:使用骨惰性示踪剂诊断 ATTR 心脏淀粉样变性只采用了有限的量化方法,但 SPECT/CT 采集可提供容积评估,并对示踪剂摄取进行量化。他法米迪是治疗心脏淀粉样变性的常规药物,但有关治疗过程中成像结果变化的数据却很少。本研究的目的是对 Tc-99m-PYP 成像进行纵向评估,以确定他法米迪治疗是否会导致示踪剂摄取的定量测量发生任何变化:这是一项前瞻性单中心研究,研究对象为接受他法米迪治疗的ATTR患者,使用Tc-99m-PYP SPECT/CT定量检测整个心脏和左心室的示踪剂摄取量。标准化摄取值(SUV)根据血池活性进行了调整。将基线活性与治疗期间大约每 6 个月获得的值进行比较:22名患者(77.0±7.5岁,86.4%为男性)接受了15.3±4.0个月的他法米迪治疗,从基线到最终随访研究的平均时间为16.8±4.7个月。13人(59.1%)进行了多次淀粉样蛋白随访研究。总 SUV、SUV 容量和注射剂量百分比均有统计学意义的明显降低。根据最大主动脉 SUV 调整后,左心室总 SUV 下降了 36.9%,SUV 容量下降了 38.7%,注射剂量百分比下降了 34.9%(所有 p 值均小于 0.0001)。在研究期间,测量指标每月下降7.7%:Tc-99m-PYP SPECT/CT的SUV定量测量结果显示,在他法米迪治疗过程中,淀粉样蛋白负荷总体下降,但还需要进一步研究,以确定最佳指标,并提高定量的可重复性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis.

Background: Cardiac imaging with bone-avid tracers for the diagnosis of transthyretin amyloid (ATTR) cardiac amyloidosis uses only limited quantification, but single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition can provide volumetric assessment with quantification of tracer uptake. Tafamidis is routinely used in the treatment of cardiac amyloidosis, but there are scant data on changes in imaging results during therapy. The purpose of this study was to perform a longitudinal assessment of Tc-99m-pyrophosphate (PYP) imaging to determine if tafamidis therapy results in any change in quantitative measures of tracer uptake.

Methods: The study incorporated a prospective, single-center study of ATTR patients being treated with tafamidis using Tc-99m-PYP SPECT/CT to quantify cardiac tracer uptake in the whole heart and left ventricle. Standardized uptake values (SUVs) were adjusted for blood pool activity. Comparison of baseline activity was made to values obtained approximately every 6 months during treatment.

Results: Twenty-two patients (77.0±7.5 years old, 86.4% male) were on tafamidis for 15.3±4.0 months, with an average time between baseline and final follow-up study of 16.8±4.7 months. Thirteen patients (59.1%) had multiple follow-up amyloid studies. Statistically significant reductions in total SUVs, SUV volume, and percentage of injected dose were seen. Adjusted for the maximal aortic SUV, the total SUV in the left ventricle decreased by 36.9%, the SUV volume by 38.7%, and the percentage of injected dose decreased by 34.9% (all P values≤0.0001). Over the study duration, there was a decrease of 7.7%/month in the measured metrics.

Conclusion: The quantitative SUV measurements from Tc-99m-PYP SPECT/CT revealed an overall decrease in scintographic amyloid burden during the course of tafamidis therapy, but additional work is needed to determine the optimal metrics and improve the reproducibility of the quantification.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.30
自引率
20.80%
发文量
249
审稿时长
4-8 weeks
期刊介绍: Journal of Nuclear Cardiology is the only journal in the world devoted to this dynamic and growing subspecialty. Physicians and technologists value the Journal not only for its peer-reviewed articles, but also for its timely discussions about the current and future role of nuclear cardiology. Original articles address all aspects of nuclear cardiology, including interpretation, diagnosis, imaging equipment, and use of radiopharmaceuticals. As the official publication of the American Society of Nuclear Cardiology, the Journal also brings readers the latest information emerging from the Society''s task forces and publishes guidelines and position papers as they are adopted.
期刊最新文献
Automatic motion correction for myocardial blood flow estimation improves diagnostic performance for coronary artery disease in 18F-flurpiridaz PET-MPI. Cardiac motion correction with a deep learning network for perfusion defect assessment in SPECT myocardial perfusion imaging. Rubidium-82 Dose Effects on Myocardial Blood Flow Measurements using a Digital PET-CT Scanner. Clinical Correlates of a Single-item Physical Activity Questionnaire among Patients Undergoing Stress SPECT Myocardial Perfusion Imaging. Splenic switch-off to assess for vasodilator non-responsiveness.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1